Seminars in Oncology
Volume 37, Issue 1 , Pages 1-10 , February 2010

Residual Disease After Neoadjuvant Chemotherapy for Breast Cancer

References 

  1. Boogerd W, Hart A, van der Sande J, et al. Meningeal carcinomatosis in breast cancer: prognostic factors and influence of treatment. Cancer. 1991;67:1685–1695
  2. Jayson G, Howell A, Harris M, et al. Carcinomatous meningitis in patients with breast cancer: an aggressive disease variant. Cancer. 1994;74:3135–3141
  3. Chamberlain MC, Johnston SK, Glantz MJ. Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol. 2009;66:74–78
  4. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778–785
  5. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–1241
  6. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–2106
  7. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.
  8. http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page7.
  9. Pullarkat V, Slovak ML, Dagis A, et al. Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: durable remissions after hematopoietic stem cell transplantation. Ann Oncol. 2009;20:2000-6.
  10. Kirova YM, De Rycke Y, Gambotti L, et al. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer. 2008;98:870–874
  11. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113:2638–2645
  12. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial [abstract]. ASCO Meeting Abstracts. 2009;27:3
  13. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676
  14. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. [abstract] J Clin Oncol 2008 ASCO Annual Meeting Proceedings. 2008;26(15S):LBA1011
  15. The NCCN Clinical Practice Guidelines in Oncology Breast Cancer (Version 1.2009). 2009 National Comprehensive Cancer Network, Inc.. NCCN.orgAccessed August 1, 2009
  16. Buchholz TA, Lehman CD, Harris JR, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008;26:791–797
  17. Tham YL, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006;107:696–704
  18. Fisher B, Bryant J, Wolmark N, et al. Effect of pre-operative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483–2493
  19. Kuerer HM, Newman LASmith Tl, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–469
  20. Kimmick GG, Cirrincione C, Duggan DB, et al. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Res Treat. 2009;113:479–490
  21. Van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224–4237
  22. Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;22:4691–4699
  23. Hellman S, Harris JR. The appropriate breast cancer paradigm. Cancer Res. 1987;47:339–342
  24. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomized trials. Lancet. 2005;365:1687–1717
  25. Chamberlain MC. Carcinomatous meningitis. Arch Neurol. 1997;54:16–17
  26. Chamberlain MC. Neoplastic meningitis. Oncologist. 2008;13:967–977
  27. Niwinska A, Jagiello-Gruszfeld AI, Rudnicka H, et al. Carcinomatous meningitis in breast cancer. J Clin Oncol ASCO Meeting Proceedings (Post-Meeting Edition). 2003;22:317
  28. Brito RA, Valero V, Buzdar AU, et al. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: the University of Texas MD Anderson Cancer Center Experience. J Clin Oncol. 2001;19:628–633
  29. Hutcheon AW, Heys SD, Sarkar TK, et al. Docetaxel primary chemotherapy in breast cancer: a five-year update of the Aberdeen trial [abstract 1]. Breast Cancer Res Treat. 2003;82:59
  30. Baer HD, Anderson S, Smith RE, et al. A randomized trial comparing preoperative doxorubicin/cyclophosphamide (AC) to preoperative AC followed by preoperative docetaxel (T) and to preoperative AC followed by postoperative T in patients with operable carcinoma of the breast: results of NSABP B-27. J Clin Oncol. 2003;21:4165–4174
  31. Buzdar A. Significantly higher pathologic complete remission rate following neoadjuvant therapy with trastuzumab [herceptin], paclitaxel and anthracycline-containing chemotherapy: initial results of a randomized trial in operable breast cancer with HER-2 positive disease. J Clin Oncol ASCO Meeting Proceedings (Post-Meeting Edition). 2004;22(14S):520
  32. Robidoux A, Buyse M, Geyer CE, et al. Neoadjuvant chemotherapy with sequential weekly nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane) followed by 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in locally advanced breast cancer (LABC): a phase II trial of NSABP Foundation research programs (FRP) [abstract 3068]. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2008, poster.
  33. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial [abstract 31]. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 12, 2008, General Session.
  34. Winter MC, Thorpe HC, Burkinshaw R, Beevers SJ, Coleman RE. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response—exploratory evidence for direct anti-tumor activity in breast cancer [abstract 5101]. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 11-13, 2008, poster.
  35. Earl HM, Vallier A, Hiller L, et al. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel +/− gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). J Clin Oncol ASCO Meeting Proceedings (Post-Meeting Edition). 2009;27(15S):522
  36. von Minckwitz G, Blohmer JU, Raab G, et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol. 2005;16:56–63
  37. Mi Z, Holmes FA, Hellerstedt B, et al. Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Res. 2008;28:1733–1740
  38. Brower SL, Fensterer JE, Bush JE. The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy. Methods Mol Biol. 2008;414:57–78
  39. Desmedt C, Azabuja E, Larsimont D, et al. Predicting the efficacy of anthracyclines in breast cancer patients: results of the neoadjuvant TOP trial. J Clin Oncol ASCO Meeting Proceedings (Post-Meeting Edition). 2009;27(15S):523
  40. De Snoo FA, Knauer M, Bender RA, et al. Outcome prediction by the 70-gene profile in the context of the National Comprehensive Cancer Network (NCCN) guidelines. J Clin Oncol ASCO Meeting Proceedings (Post-Meeting Edition). 2009;27(15S):535
  41. Huober J, von Minckwitz G, Denkert C, et al. Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): final results and analysis of markers predicting response to treatment. J Clin Oncol ASCO Meeting Proceedings (Post-Meeting Edition). 2009;27(15S):524
  42. Yardley DA, Raefsky E, Castillo R, et al. Results of a mulicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives. J Clin Oncol ASCO Meeting Proceedings (Post-Meeting Edition). 2009;27(15S):527
  43. DeMichele A, Dunn L, Gimotty P, et al. Loss of p27 expression and response to neoadjuvant chemotherapy: results from the I-SPY Trial (CALGB 150007/150012, ACRIN6657). J Clin Oncol ASCO Meeting Proceedings (Post-Meeting Edition). 2009;27(15S):11091
  44. Schnitt SJ, Collins LC. In: Biopsy interpretation of the breast. Philadelphia: Lippincott Williams & Wilkins; 2009;p. 443–446
  45. Liedtke C, Hatzis C, Symmans WF, et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol. 2009;27:3185–3191

PII: S0093-7754(09)00226-7

doi: 10.1053/j.seminoncol.2009.12.001

Seminars in Oncology
Volume 37, Issue 1 , Pages 1-10 , February 2010

Article Tools

* Image Usage & Resolution